National Health Service Act 2006

[F12(1)[F2NHS England] must determine the elements of pharmaceutical remuneration in respect of which apportionments are to be made in relation to a financial year in accordance with this paragraph.E+W

(2)In this Schedule, those elements of pharmaceutical remuneration are referred to as “designated elements”.

(3)[F2NHS England] must notify each [F3integrated care board] of a determination under sub-paragraph (1).

(4)[F2NHS England] must apportion the sums paid by it in respect of each designated element during the financial year among all [F4integrated care boards], in such manner as [F2NHS England] thinks appropriate.

(5)In apportioning sums under sub-paragraph (4), [F2NHS England] may, in particular, take into account the financial consequences of orders for the provision of drugs that are attributable to the members of each [F5integrated care board].

(6)Where an amount of pharmaceutical remuneration is apportioned to [F6an integrated care board], [F2NHS England]—

(a)may deduct that amount from the sums that it would otherwise pay to [F7the board] under section 223G(1), and

(b)if it does so, must notify [F8the board] accordingly.

(7)The Secretary of State may direct [F2NHS England] that an element of pharmaceutical remuneration specified in the direction is not to be included in a determination under sub-paragraph (1).

(8)In determining the amount to be allotted to [F9an integrated care board] for the purposes of section 223G, [F2NHS England] must take into account the effect of this Schedule.

[F10(9)For the purposes of sections 223GC and 223M(1)(b) and paragraph 22 of Schedule 1B, any amount of which an integrated care board is notified under sub-paragraph (6) is to be treated as expenditure of the group which is attributable to the performance by it of its functions in the year in question.]]

Textual Amendments